Anchiano Therapeutics

Company Overview

Snapshot

Founded in October 2004 by Prof. Avraham Hochberg (Late), Anchiano Therapeutics operated with 1–10 employees. The company raised a total of $37.7M across 6 funding rounds from 2 investors. A significant milestone for the company was its acquisition by Chemomab Therapeutics in March 2021.

Business overview

Anchiano Therapeutics was a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for cancer-related diseases. Its core product candidate, BC-819, was under development for non-muscle-invasive bladder cancer, while BC-821 was being developed for systemic treatment of advanced malignant neoplasms. The company operated within the Health Tech & Life Sciences sector, specifically focusing on Pharmaceuticals & Medical Biotechnology and Medical Treatment & Therapeutics, serving markets in Japan, Europe, and the United States.

Strategic signal

In March 2021, Anchiano Therapeutics completed its merger with Chemomab Therapeutics, following shareholder approval and a $45.5M private financing. This event marked a strategic shift for Anchiano, transitioning from an independent entity to becoming part of a larger biopharmaceutical organization, signaling a consolidation within the cancer therapy development landscape and a potential acceleration of its pipeline under new ownership.

Company Intelligence Q&A

What was a significant corporate event for Anchiano Therapeutics in March 2021?

In March 2021, Anchiano Therapeutics completed its merger with Chemomab Therapeutics. This event followed shareholder approval and a $45.5M private financing round.

When did Anchiano Therapeutics announce its initial public offering on Nasdaq?

In February 2019, Anchiano Therapeutics announced the pricing of its $30.5 million initial public offering on Nasdaq.

Which investor participated in a PIPE funding round for Anchiano Therapeutics in October 2016?

In October 2016, Palisade Capital Management participated in a PIPE funding round for Anchiano Therapeutics.

What was the outcome of Anchiano Therapeutics' listing on the TASE in April 2021?

In April 2021, Anchiano Therapeutics was delisted from the TASE due to its acquisition by Chemomab Therapeutics.

What was the primary focus of Anchiano Therapeutics' product development?

Anchiano Therapeutics focused on developing targeted cancer therapies. Its lead product candidate, BC-819, was for non-muscle-invasive bladder cancer, and BC-821 was for systemic treatment of advanced malignant neoplasms.